Physician profile
Bryan Fiema
NPI 1164943924
$2,671.94
in general payments reported to CMS, 2019-2025
28 companies · $499 in 2025
The $499 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $210 · 2020: $271 · 2021: $509 · 2022: $534 · 2023: $322 · 2024: $327 · 2025: $499.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,148.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,148.17 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $356.30 | 2020-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $204.93 | 2022-2025 | Jardiance |
| Edwards Lifesciences Corporation | $204.24 | 2021-2025 | Sapien 3 Ultra Resilia |
| Novartis Pharmaceuticals Corporation | $204.07 | 2024-2025 | |
| Abbott Laboratories | $184.29 | 2021-2022 | |
| E.R. Squibb & Sons, L.L.C. | $173.70 | 2023-2025 | Camzyos |
| Astellas Pharma US INC | $165.48 | 2021-2022 | |
| Pfizer INC. | $147.51 | 2019-2025 | |
| Cvrx, INC. | $137.15 | 2023 | Barostim Neo System |
| Medtronic, INC. | $129.45 | 2022-2023 | Linq II |
| Astrazeneca Pharmaceuticals Lp | $120.12 | 2019-2025 | Farxiga |
| W. L. Gore & Associates, INC. | $98.66 | 2022 | |
| Novo Nordisk INC | $87.38 | 2019-2025 | Wegovy |
| Scpharmaceuticals INC. | $76.42 | 2024-2025 | |
| Kestra Medical Technology Services, INC. | $53.84 | 2024 | Assure Wcd |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Inspire Medical Systems, INC. | $48.77 | 2024-2025 | Inspire |
| Merck Sharp & Dohme LLC | $41.53 | 2025 | Verquvo, Capvaxive |
| Janssen Pharmaceuticals, INC | $38.36 | 2024 | Xarelto |
| Amgen INC. | $35.02 | 2024-2025 | Repatha, Repatha |
| Abiomed | $28.87 | 2021-2022 | |
| Lantheus Medical Imaging, INC. | $22.24 | 2025 | |
| Regeneron Healthcare Solutions, INC. | $18.23 | 2024 | Evkeeza |
| Allergan, INC. | $17.05 | 2019 | |
| Alnylam Pharmaceuticals INC. | $16.94 | 2024 | Onpattro |
| Abbvie INC. | $16.14 | 2019 | |
| Daiichi Sankyo INC. | $15.66 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $15.12 | 2025 | |
| Bridgebio Pharma, INC. | $14.47 | 2025 | Attruby |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bryan Fiema listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.